BioLife Solutions: A Steady Stock Lined Up For Success In A Booming Industry
BioLife Solutions, an established biotech firm, is poised to benefit from the booming cell and gene therapy sector, projected to grow significantly by 2030. Despite recent negative EPS, BioLife has consistently exceeded earnings expectations, indicating strong future potential and investor confidence. BioLife's unique focus on cell preservation and storage positions it advantageously within the CGT sector, with expected revenue growth heavily outpacing peers.
5 Low-Leverage Stocks to Buy Amid Trump's Tariff Woes
The majority of U.S. stock indices ended barely in the green on March 21, 2025, overcoming their recent losing streaks since investors remain wary about the long-term economic impacts of President Trump's enhanced import tariffs. The latest uptick in the major stock indices was mostly because the Federal Reserve kept its projection for interest rate cuts broadly unchanged, indicating economic stability for the time being.
BioLife Solutions, Inc. (BLFS) Reports Q4 Loss, Tops Revenue Estimates
BioLife Solutions, Inc. (BLFS) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.30 per share a year ago.
Recent Price Trend in BioLife Solutions (BLFS) is Your Friend, Here's Why
BioLife Solutions (BLFS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
BioLife Solutions, Inc. (BLFS) Hit a 52 Week High, Can the Run Continue?
BioLife Solutions (BLFS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Is BioLife Solutions (BLFS) Stock Outpacing Its Medical Peers This Year?
Here is how BioLife Solutions, Inc. (BLFS) and Ginkgo Bioworks Holdings, Inc. (DNA) have performed compared to their sector so far this year.
BioLife Solutions (BLFS) Is a Great Choice for 'Trend' Investors, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, BioLife Solutions (BLFS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
BioLife Solutions price target raised to $31 from $28 at Northland
Northland raised the firm's price target on BioLife Solutions to $31 from $28 and keeps an Outperform rating on the shares. With the divestiture of its freezer businesses and the recent sale of SciSafe biostorage, the firm believes BioLife is positioned to "emerge as a leading consolidator in the sector" as the company refocuses on its core expertise in biopreservation media and cell processing products and services for cell and gene therapies, the analyst tells investors.
BioLife Solutions, Inc. (BLFS) Q3 2024 Earnings Call Transcript
BioLife Solutions, Inc. (NASDAQ:BLFS ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Troy Wichterman - Chief Financial Officer Rod de Greef - Chairman and Chief Executive Officer Garrie Richardson - Chief Revenue Officer Conference Call Participants Matt Stanton - Jefferies Brendan Smith - TD Cowen Anna Snopkowski - KeyBanc Matt Hewitt - Craig-Hallum Capital Group LLC Thomas Flaten - Lake Street Capital Markets Jade Montgomery - H.C. Wainwright & Co., LLC Operator Good afternoon, ladies and gentlemen, and thank you for standing by.
BioLife Solutions, Inc. (BLFS) Reports Q3 Loss, Tops Revenue Estimates
BioLife Solutions, Inc. (BLFS) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.67 per share a year ago.
Are Medical Stocks Lagging BioLife Solutions (BLFS) This Year?
Here is how BioLife Solutions, Inc. (BLFS) and Eli Lilly (LLY) have performed compared to their sector so far this year.
Here's Why Momentum in BioLife Solutions (BLFS) Should Keep going
BioLife Solutions (BLFS) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
